Facing Cancer Drug Shortage, U.S. Relies on Banned Chinese PlantBy
Chinese factory on FDA’s ban list after failing inspection
15 exempted products still allowed in the U.S. market
Last September, U.S. regulators faced a dilemma: whether to allow importation of drug ingredients from a Chinese factory with a history of poor quality controls, or face shortages of treatments for American cancer patients.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.